An interventional study of Doxercalciferol administration and oral calcitriol 0.25 microgram in Lowering Parathyroid Hormone Level in Patients on Hemodioalysis, sponsored by Chittagong Medical College. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Chittagong Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Secondary hyperparathyroidism (SHPT) is a common complication of advanced chronic kidney disease (CKD), caused by phosphate retention and vitamin D deficiency, leading to elevated parathyroid hormone (PTH) levels and increased bone and cardiovascular complications. Active vitamin D analogs such as calcitriol and doxercalciferol are used to suppress PTH levels, though they differ in pharmacologic properties and effects on mineral metabolism. Intravenous preparations may offer improved bioavailability and adherence in hemodialysis patients.This randomized controlled trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital among 98 adult hemodialysis patients with SHPT. Participants will be randomly assigned to receive either intravenous doxercalciferol or oral calcitriol. The study aims to compare their effectiveness in lowering PTH levels and evaluate safety outcomes.
Continuous variables will be expressed as mean ± standard deviation, while categorical variables will be presented as frequencies and percentages. Independent t-tests, chi-square tests, or Fisher's exact tests will be used for statistical comparisons. Data analysis will be performed using SPSS version 27.0, with a p-value \<0.05 considered statistically significant.
Secondary hyperparathyroidism (SHPT), characterized by markedly elevated parathyroid hormone (PTH) levels, arises from the metabolic abnormalities associated with end-stage renal disease (ESRD). It affects the majority of patients undergoing dialysis and contributes to a wide range of complications, including cognitive impairment, bone disease, and cardiovascular morbidity. SHPT develops early during chronic kidney disease (CKD), often beginning in stage G2, when impaired phosphate excretion stimulates increased secretion of PTH. As kidney function declines further, hyperphosphatemia and hypocalcemia become more pronounced, leading to progressive parathyroid gland hyperplasia and excessive hormone production.
Clinically, SHPT is a major component of chronic kidney disease-mineral and bone disorder (CKD-MBD), which is characterized by bone pain, skeletal deformities, spontaneous fractures, soft tissue calcification, and muscle weakness. Persistent elevations in PTH also contribute to vascular calcification, left ventricular hypertrophy, and other cardiovascular complications that significantly increase morbidity and mortality among dialysis patients. Consequently, uncontrolled SHPT adversely affects both quality of life and long-term survival.
Parathyroid hormone plays a central role in calcium and phosphate homeostasis. It maintains serum calcium levels by stimulating bone resorption and enhancing calcium mobilization from the skeleton. Although PTH increases phosphate release from bone, it also promotes phosphate excretion through the kidneys by reducing tubular phosphate reabsorption. In patients with CKD, these regulatory mechanisms become impaired, resulting in chronic elevations of PTH and progressive disturbances in mineral metabolism. Sustained hyperparathyroidism can lead to high-turnover bone disease, renal osteodystrophy, vascular calcification, and increased cardiovascular risk.
Intravenous doxercalciferol and oral calcitriol are commonly used vitamin D receptor activators for the management of SHPT in hemodialysis patients. Calcitriol, the active form of vitamin D, directly binds to vitamin D receptors and effectively suppresses PTH secretion. However, its use is frequently associated with increases in serum calcium and phosphate levels, potentially increasing the risk of vascular calcification. Doxercalciferol, a synthetic vitamin D analog, requires hepatic activation and has been shown to provide effective PTH suppression while producing fewer calcemic effects. These pharmacological differences may influence treatment outcomes and safety profiles in dialysis populations.
Recent evidence suggests that both agents are effective in reducing PTH levels, although intravenous doxercalciferol may offer improved biochemical control and a lower incidence of hypercalcemia. As secondary hyperparathyroidism remains highly prevalent among hemodialysis patients, identifying the most effective and safest therapeutic option is of considerable clinical importance.
In Bangladesh and other low- and middle-income countries, the growing burden of CKD and dependence on maintenance hemodialysis present substantial healthcare challenges. Medication cost, availability, and patient adherence play important roles in treatment selection. Oral calcitriol is widely available and relatively inexpensive, whereas intravenous doxercalciferol may be less accessible in resource-constrained settings. Furthermore, adherence to oral therapy may be affected by pill burden and other practical barriers. Therefore, evidence comparing the efficacy and safety of these treatment options is essential for guiding cost-effective and evidence-based clinical practice.
Despite the widespread use of both agents, high-quality comparative studies in hemodialysis patients from resource-limited settings remain limited. Most available evidence originates from high-income countries, and its applicability to South Asian populations is uncertain. A direct comparison of intravenous doxercalciferol and oral calcitriol with respect to PTH control, biochemical outcomes, safety, and treatment practicality is therefore warranted. This study aims to address this knowledge gap and provide evidence to support optimal management of secondary hyperparathyroidism among hemodialysis patients in resource-constrained environments.
Chittagong Medical College is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental subjects will receive an intravenous loading dose of doxercalciferol 4 micrograms after dialysis, in addition to their standard routine medications. Each Dose of doxercalciferol will be given after skin sensitivity test
Drug: Doxercalciferol administration
Control group will receive oral calcitriol 0.25 microgram once daily in addition to their standard routine medications for 12 weeks
Drug: oral calcitriol 0.25 microgram
receive iv doxercalciferol 4 microgram after dialysis for 12 weeks in addition to their standard routine medications.
Control group will receive oral calcitriol 0.25 microgram once daily in addition to their standard routine medications for 12 weeks
Change in serum Parathyroid Hormone (PTH) levels
Patients undergoing hemodialysis with secondary hyperparathyroidism will receive intravenous doxercalciferol according to a standardized dosing protocol. The dose will be adjusted based on serum parathyroid hormone (PTH), calcium, and phosphate levels measured periodically. The aim is to evaluate the effectiveness of doxercalciferol in reducing PTH levels
Time frame: 12 weeks
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Jul 2026; primary completion for May 2027, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chittagong Medical College